SEOM Clinical guidelines for the treatment of advanced colorectal cancer 2013

被引:20
作者
Casado-Saenz, E. [1 ]
Feliu, J. [2 ]
Gomez-Espana, M. A. [3 ]
Sanchez-Gastaldo, A. [4 ]
Garcia-Carbonero, R. [4 ]
机构
[1] Hosp Infanta Sofia, Dept Med Oncol, Madrid, Spain
[2] Hosp La Paz, Dept Med Oncol, Madrid, Spain
[3] Hosp Reina Sofia, Dept Med Oncol, Cordoba, Spain
[4] Univ Seville, CSIC, Inst Biomed Sevilla IBIS, Serv Oncol Med,Hosp Univ Virgen Rocio,HUVR, Seville 41013, Spain
关键词
Colorectal cancer; Guidelines; Chemotherapy; Surgery; PHASE-III TRIAL; CETUXIMAB PLUS IRINOTECAN; 1ST-LINE TREATMENT; LIVER METASTASES; INFUSIONAL FLUOROURACIL; LEUCOVORIN; OXALIPLATIN; CHEMOTHERAPY; BEVACIZUMAB; PANITUMUMAB;
D O I
10.1007/s12094-013-1082-5
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
Colorectal cancer (CRC) is the most common malignant tumor in Western countries. Despite efforts made to implement screening programmes for early detection and treatment, still half of the patients present or will eventually develop distant metastasis. Management of advanced CRC should be discussed within an experienced multidisciplinary team, to adequately select the most appropriate systemic therapeutic option, as well as the optimal way to integrate it with surgical procedures when indicated. Disease localization and extent, resectability of primary and metastatic disease, tumor biology and dynamics, clinical symptoms, personal preferences and patient's ability to tolerate intensive chemotherapy or extensive surgical procedures are the key factors to properly design a customized treatment plan. The aim of the current manuscript is to provide synthetic practical guidelines regarding therapeutic options for advanced CRC.
引用
收藏
页码:996 / 1003
页数:8
相关论文
共 28 条
[1]
Abdalla EK, 2004, ANN SURG, V239, P818, DOI 10.1097/01.sla.0000128305.90650.71
[2]
Adam R, 2004, ANN SURG, V240, P644, DOI 10.1097/01.sla.0000141198.92114.16
[3]
Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial [J].
Bennouna, Jaafar ;
Sastre, Javier ;
Arnold, Dirk ;
Osterlund, Pia ;
Greil, Richard ;
Van Cutsem, Eric ;
von Moos, Roger ;
Maria Vieitez, Jose ;
Bouche, Olivier ;
Borg, Christophe ;
Steffens, Claus-Christoph ;
Alonso-Orduna, Vicente ;
Schlichting, Christoph ;
Reyes-Rivera, Irmarie ;
Bendahmane, Belguendouz ;
Andre, Thierry ;
Kubicka, Stefan .
LANCET ONCOLOGY, 2013, 14 (01) :29-37
[4]
Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study [J].
Bokemeyer, C. ;
Bondarenko, I. ;
Hartmann, J. T. ;
de Braud, F. ;
Schuch, G. ;
Zubel, A. ;
Celik, I. ;
Schlichting, M. ;
Koralewski, P. .
ANNALS OF ONCOLOGY, 2011, 22 (07) :1535-1546
[5]
Association of high-throughput RNAi and drug screening with candidate novel therapeutic targets in esophageal carcinoma [J].
Chong, Irene Yu-Shing ;
Hooper, Sean D. ;
Cunningham, David ;
Elliott, Richard ;
Chen, Lina ;
Campbell, James ;
Bajrami, Ilirjana ;
Kozarewa, Iwanka ;
Wetterskog, Daniel ;
Wilkerson, Paul M. ;
Lambros, Maryou B. ;
Rao, Sheela ;
Starling, Naureen ;
Chau, Ian ;
Lord, Christopher J. ;
Ashworth, Alan .
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
[6]
Trends in long-term survival following liver resection for hepatic colorectal metastases [J].
Choti, MA ;
Sitzmann, JV ;
Tiburi, MF ;
Sumetchotimetha, W ;
Rangsin, R ;
Schulick, RD ;
Lillemoe, KD ;
Yeo, CJ ;
Cameron, JL .
ANNALS OF SURGERY, 2002, 235 (06) :759-765
[7]
Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer [J].
Cunningham, D ;
Humblet, Y ;
Siena, S ;
Khayat, D ;
Bleiberg, H ;
Santoro, A ;
Bets, D ;
Mueser, M ;
Harstrick, A ;
Verslype, C ;
Chau, I ;
Van Cutsem, E .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (04) :337-345
[8]
Cytoreductive surgery and HIPEC for peritoneal metastases combined with curative treatment of colorectal liver metastases Systematic review of all literature and meta-analysis of observational studies [J].
de Cuba, E. M. V. ;
Kwakman, R. ;
Knol, D. L. ;
Bonjer, H. J. ;
Meijer, G. A. ;
te Velde, E. A. .
CANCER TREATMENT REVIEWS, 2013, 39 (04) :321-327
[9]
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer [J].
de Gramont, A ;
Figer, A ;
Seymour, M ;
Homerin, M ;
Hmissi, A ;
Cassidy, J ;
Boni, C ;
Cortes-Funes, H ;
Cervantes, A ;
Freyer, G ;
Papamichael, D ;
Le Bail, N ;
Louvet, C ;
Hendler, D ;
de Braud, F ;
Wilson, C ;
Morvan, F ;
Bonetti, A .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (16) :2938-2947
[10]
Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study [J].
Douillard, Jean-Yves ;
Siena, Salvatore ;
Cassidy, James ;
Tabernero, Josep ;
Burkes, Ronald ;
Barugel, Mario ;
Humblet, Yves ;
Bodoky, Gyoergy ;
Cunningham, David ;
Jassem, Jacek ;
Rivera, Fernando ;
Kocakova, Ilona ;
Ruff, Paul ;
Blasinska-Morawiec, Maria ;
Smakal, Martin ;
Canon, Jean-Luc ;
Rother, Mark ;
Oliner, Kelly S. ;
Wolf, Michael ;
Gansert, Jennifer .
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (31) :4697-4705